Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $72.50 short call and a strike $77.50 long call offers a potential 8.46% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $72.50 by expiration. The full premium credit of $0.39 would be kept by the premium seller. The risk of $4.61 would be incurred if the stock rose above the $77.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is at 31.22 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Taiwan provisionally approves dexamethasone as coronavirus treatment
Tue, 04 Aug 2020 08:26:42 +0000
Taiwan provisionally approved the use of dexamethasone, a cheap and widely-used steroid, to treat the new coronavirus, as the island faces a shortfall of the antiviral drug remdesivir after the United States bought nearly all global supplies. Taiwan Centres for Disease Control Deputy Director-General Chuang Jen-hsiang told reporters on Tuesday that medical experts had decided to provisionally allow dexamethasone to be listed as a COVID-19 treatment but that procedures still needed to be completed before it could be given to any patients. Taiwan has reported 476 cases of the new coronavirus, including seven deaths.
Gilead Stock Is Rising Because Covid-Treatment Sales Could Top $3 Billion
Mon, 03 Aug 2020 16:46:00 +0000
Sales of its Covid-19 treatment could be worth more than $3 billion this year for Gilead Sciences, Citigroup’s Mohit Bansal says.
Rival drugmakers launch joint trial of medicines for COVID-19
Mon, 03 Aug 2020 09:45:00 +0000
Rival drugmakers AbbVie Inc, Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus. The COVID-19 pandemic is an “all hands on deck moment,” David Reese, Amgen's research and development chief told Reuters. “We wanted a trial to be able to quickly sift through multiple agents and prioritize.”
Better Buy: Gilead Sciences vs. Pfizer
Sat, 01 Aug 2020 14:44:00 +0000
Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Recently, Gilead has been in the headlines thanks to its much-discussed antiviral drug remdesivir, which appears to be somewhat beneficial for treating coronavirus infections in certain patient populations. It helps that Gilead was an attractive company well before the pandemic, with normalized trailing 12-month diluted earnings per share (EPS) of $3.90 in contrast with Pfizer's $1.98 and a robust profit margin of 21.8%, slightly trailing Pfizer's 28.8%.
Gilead Sciences (GILD) Q2 2020 Earnings Call Transcript
Sat, 01 Aug 2020 05:33:33 +0000
GILD earnings call for the period ending June 30, 2020.
Also on Market Tamer…
Follow Us on Facebook